1357
ONKOLOGIE3418043010760120167227269329388409453
/8408043010731
Onkologie.9168043010761110147195214263313331375390
2023;17(5):357-3621326804301074487128172186223260280323345360404446488511552595637
/20088043010732
www.onkologiecs.cz48658043010765133201214262311348396415464514532576617652669709748
3621268026012657114172
PŘEHLEDOVÉ341207012660124182256312369444520587645
ČLÁNKY1008207012660115187259327395
Kardiovaskulární34136501063375111151168209246283317352393424466501543560
nežádoucí91736501063971106147186227269303321
účinky12543650106387391132167206
inhibitorů14763650106155697115150168200239275316
signálních18083650106304787128168199240258292333
drah215736501063773115156
v2328365010637
terapii23803650106306298140174192209
chronické260436501063374110150192209244280312
lymfocytární293236501062961115146187222261295331367408426
leukemie337336501062962102138170225242274
LITERATURA34158001234978134189250318368438498567
1.3407400853647
Hernández399741083447899136168205243277306
JA,716741083246377
Land8047410833164101139
KJ,955741083356273
McKenna10407410835485120153190227259
RW.13107410833693102
Leukemias,14237410833265102131164221236267293305
myeloma,17397410835787121135173230262274
and3408410833168105
other455841083375894127147
lymphoreticular6138410831444101138175212232264285299330366380410430
neoplasms.10548410833670107145159190215270295307
Cancer.13728410833970107137169189198
1995;75:381-394.1581841083336296128138169200210243276306324354386420431
https://doi.org/10.1002/1097-0142(19950101)75:1+<381::AID-34094108338598312314916218820824428229731034836940743346649851054157260864166770073276780081885588791895096799910291064109811321164119512271241127213051315134513831425145914931525153315461588160316491672
-CNCR2820751320>3.0.CO;2-B.34010410832163107147182217250283316348380411440472505546576587622634673717729764783820832
2.34011400853652
Smith40911410833290105128166
A,59211410834155
Howell66411410834482133168183198
D,87911410834657
Patmore9531141083356788147185206241
R,121111410833549
et127711410833456
al.13501141083324760
Incidence14271141083155385100139174212244278
of172211410833756
haematological1795114108338701051631953401241083226077116156172205239255
malignancy61612410835992108124164203236275308343
by98012410833971
sub-type:107312410832665105129152187228265278
a1372124108332
report14261241083215696136158184
from16311241083194280140
the17921241083226197
Haematological19111241083457834013410833594127150187204243284299332366382
Malignancy74313410835689105121160199233272305339
Research110313410833672100136169190222261
Network.138613410834581104158197219251266
Br167313410833658
J1753134108324
Cancer.179913410834074113146181203213
2011;105:1684-92.34014410833468100128136166198232243272303339375398433466479
https://doi.org/10.1038/bjc.2011.450.834144108338598412315016218921024528329931235037141043646950051354457560864366870872475676980583987189890894297510091022
3.34015400853651
Larsson4121541083326687115142180219
K,65215410833550
Mattsson72315410835588110135163190228267
M,101115410835569
Ebrahim11011541083327294127166181240
F,136115410833339
et142115410833457
al.14991541083324760
High15801541083456099138
prevalence1739154108339619512816117721225134016410833165
and42516410833169108
incidence5531641083155285100139173212244277
of85016410833757
cardiovascular9261641083316485124139177209242268300338353386407
disease13521641083385480115147173208
in158016410831452
chronic16521641083316990127166181213
lymphocytic18851641083144610534017410833977115148182206222254
leukaemia:6101741083144987117151186243259291303
a929174108332
nationwide9761741083387092107145184234250289324
population-based131517410833978118156171203225240278317339379412439474513
study.18441741083264987126158168
Br34018410833557
J412184108324
Haematol.45218410834476111169201223260276289
2020;190.75618410833468101135148178208244257
https://doi.org/10.1111/bjh.16859.10281841083385983123150162189209245283299312350371409436469500513543571599626648688704742755786817852886919930
4.34019400853652
Byrd4131941083366890129
JC,5631941083246579
Brown6621941083365895147186
JR,8691941083246175
O’Brien9651941083476097119135170209
S,119419410833346
et126119410833457
al.13391941083324760
Ibrutinib14201941083155577115138154192207247
versus16881941083326688115153180
Ofatumumab18881941083486810234020410832260118156214247287
in64720410831553
Previously7212041083355690123139177216242258290
Treated10312041083335085117139173213
Chronic126420410834079100138176192224
Lymphoid150820410833261120159198237252291
Leukemia.18202041083326610413416934021410835772104117
N470214108345
Engl52721410833370109124
J664214108324
Med.70121410835489129142
2014;371:213-223.8562141083346799130142177208241249284315345367398432467479
https://doi.org/10.1056/13482141083375983122149161188208244282297310348369407433466497510540572605640665
NEJMoa1400376.34022410834578105159198231261292328364397429461474
5.34023400853650
Ahn40223410834178116
IE,5302341083154760
Brown6022341083355693143181
JR.7962341083245973
Targeting8822341083326080118152174189226265
Bruton’s11592341083355694116152190202226
Tyrosine13982341083325981117144158195230
Kinase16402341083355188120146181
in183323410831452
CLL.189723410834071102116
Front3402441083325289127149
Immunol.50224410831572130167205244259272
2021;12:687458.78724410833468101132141171200213248284316347379414427
https://doi.org/10.3389/fimmu.2021.687458.1227244108337598312214916118820924428229831034837040843446749851154657961364867168970676334025410835795108144178211243252287323356386419453466
6.34026400853652
Estupiñán4122641083336083121160176214246284
HY,7162641083458089
Berglöf8252641083357092130145183203
A,104826410834155
Zain11232641083387186124
R,126726410833549
et133726410833456
al.14132641083324760
Comparative149326410834077136175208229262284299331366
Analysis187926410834179111340274108315477489116
of47627410833857
BTK55427410833669106
Inhibitors6812741083155391107146162185222244271
and97327410833270110
Mechanisms110327410835591124162194233248274333359
Underlying148327410834482121157178194226242280320
Adverse18232741083428011314816934028410832763
Effects.4252841083335372108142167195210
Front6562841083335493132155
Cell8322841083417693108
Dev96228410834683116
Biol.11002841083365291108122
2021;9:630942.124328410833571105137146183197233268304340377411424
https://doi.16892841083386186127155168196217254293310323
org/10.3389/fcell.2021.630942.3402941083375997123156188200236269303337361380411445461476489525559592623633668702736771807840852
7.34030400853645
Kaptein40330410833568108130163179217
A,63730410834156
De71030410834681
Bruin8093041083355795110148
G,97530410834457
Emmelot-van105030410833390148183199237259278311344382
Hoek145030410834482118148
M,161630410835568
Van170230410833667105
De182530410834580
Kar19233041083356990
B,34031410833548
De40831410834581
Jong50931410832462101140
A,66931410834155
Gulrajani7443141083448297118151167199237252
M,101631410835568
et110431410833456
al.11813141083314760
Potency12613141083357294127165198231
and151231410833270109
Selectivity16413141083336883118151175190223239261295
of195631410833756
BTK34032410833569105
Inhibitors4623241083155391106145161183220242269
in74832410831553
Clinical8183241083395570107123154187203
Development103832410834580113147163201240299334372393
for14483241083195678
B-Cell154332410833558101135150165
Malignancies.1725324108355871031181561942272653403341083314681108121
Blood.4823341083355189128167180
2018;132:1871-1871.68333410833468100131143173203235248278309342374393424455488520529
https://doi.org/10.1182/blood-2018-99-109973.123333410833759831221491621892092452832983113493714094354685005125435716026356627027187563403441083377799130164196227250285320343374406441476509543556
8.34035400853754
Smolej41735410833393133150187203
L.64335410833247
On71335410834889
the8253541083226298
road9463541083226195136
to110535410832261
optimized118935410833880103119179195226261303
BTK151535410833671109
inhibition16473541083155595111152168192208248288
in195835410831555
CLL.34036410834174108123
Blood.4873641083365393134175189
2021;137:3313-4.70136410833571105138147179211244255292327359391414452466
https://doi.org/10.1182/blood.2021011462.119136410833962881291571711992212582983153293683914314594945275405736026346706987407577973403741083377790126160193224256288315346382416428
9.34038400853649
Mato40538410835487109146
AR,5663841083417791
Shah67338410833270102140
NN,82938410834590103
Jurczak9473841083256284115145179209
W,117238410835767
et125438410833457
al.13263841083324760
Pirtobrutinib1402384108335497195132172193232254269307322361
in177938410831553
relapsed1847384108321557110314234039410832662102
or46239410833860
refractory543394108321557497130163187225246281
B-cell8453941083355893127142158
malignancies102439410835790106121160199231270302318353380
(BRUIN):14253941083185591136152197216228
a1674394108332
phase172739410833978111138173
1/219213941083345692
study.3404041083264987126158167
The52040410833372107
Lancet63940410833265103135168191
2021;397:892–901.84240410833468101132141175208241251286320353387422457489498
https://doi.org/10.1016/13534041083375983122149161188208244282297310348369407433466497510541572603635659
S0140-6736(21)00224-5.3404141083326799130166190227260294329348382413428463499532567598621655667
10.3404240085367085
McMullen43942410835487142180195210245283
JR,7374241083246074
Boey82542410833674110141
EJH,98142410833259104116
Ooi111242410834786101
JYY,12274241083256199108
et134942410833456
al.14204241083314760
Ibrutinib14944241083155476114136152190205244
increases17524241083155385106140172199234261
the3404341083226095
risk450434108321376393
of55843410833857
atrial631434108331537590122138
fibrillation,784434108317347395110126141173195210248286299
potentially10994341083387799133171192208240255270302
through14174341083215981118156195233
inhibition16664341083145290105144160182198236274
of195643410833756
cardiac3404441083316485123139171203
PI3K-Akt5604441083355084119138180210234
signaling.8124441083264180118150165180218257270
Blood.11004441083355189128167181
2014;124:3829-30.129844410833468100131143173203235247282317350384408440475488
https://18034441083385984123150162189209
doi.org/10.1182/blood-2014-10-604272.34045410833876921051431642032292622933063373643954294554965115505886286506817157477788018328638879249609961029106210961108
11.3404640085366678
Weeks43246410835791126156185
KL,6304641083356882
Gao72546410834476115
X,85346410833851
Du91746410834684
X-J,1014464108338587991
et111846410833457
al.11884641083314760
Phosphoinositide126146410833572111137176215253269307345372386409424463498
3-Kinase17724641083345693109147179206241
p110α3404741083396997128167
Is52447410831440
a581474108332
Master62947410835487114137170192
Regulator83747410833570110148163195217254275
of112947410833756
Exercise-Induced12024741083326599120151166192227251267305344382414448487
Cardioprotection170547410834073941331481862252472843404841083225588112127165204
and56148410833270109
PI3K6884841083354983118
Gene82348410834479118153
Therapy99348410833272107128161200231
Rescues12424841083357097129167202229
Cardiac14884841083407394132147179212
Dysfunction.1717484108345781051251642022342582733404941083377689
Circ:4424941083405576107120
Heart57549410834479111132157
Failure.744494108333627792130151185197
2012;5:523-34.95449410833468100130142177188223256291313345380393
https://doi.org/10.1161/13604941083375983122149162188209244282298311349370408434467499511542570601631653
CIRCHEARTFAILURE.112.966622.3405041083405591131176209252287321355393408440483519552566596624654666700735771806840875887
12.3405140085376986
Li44751410833248
X,51651410833953
Wang59051410835890129169
A,78151410834156
Yu85851410833672
K,95151410833651
et102351410833557
al.11025141083324861
Discovery11855141083466288122159192227249284
of149051410833858
(R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-115695141083191588514208335162451410831942749311414817119222524929135136634052410833979104139162184219244286327364404445477513555596633673706723744769801
H-pyrazolo[3,4-d]pyrimidin-117152420834312185241083216497121156187227244284305342355392417163852420833616795241083196093117134195211252269309333
-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone34053410832153731061231431831992402772993153553714104344664855185355555796116326536917077678038268658979149471007102310621102112011561179121912521291133113711407
(CHMFL-176853410831960106162197229244
-FLT3-122)3405441083215586115151173204233268286
as64254410833158
a716544108331
Potent7635441083357294127165187
and96654410833169108
Orally109054410834769102117132164
Available126954410834172105120135167207223257
FLT315425441083326392128
Kinase16865441083355189121148183
Inhibitor188454410831553911063405541083395477114135
for4955541083195678
FLT3-ITD5935541083326392128150166201247
Positive8605541083367299114136152184218
Acute109855410834173111133167
Myeloid128555410835486120136174189228
Leukemia.153355410833266103134168226241273286
J1839554108324
Med188355410835590129
Chem.34056410834180116175189
2015;58:9625-38.55056410833570103134145181216229265302336372395428463477
https://doi.org/10.1021/acs.jmedchem.5b01611.1049564108338608512615316619421525229130732136038242144848251552856059262665868171274577478880586490094034057410833169104162175211249285317348378406415
13.3405840085366883
Xiao4365841083385385123
L,57258410833245
Salem6305841083336581116173
J-E,816584108325478295
Clauss9245841083405587124151177
S,111458410833345
et117258410833457
al.12425841083314760
Ibrutinib-Mediated13155841083145375113136151189204243266322357397412444465499539
Atrial1867584108340628399131146
Fibrillation3405941083324785106122137151183204219257295
Attributable6475941083416285106122160198220252291307341
to100059410832258
Inhibition10715941083145289104143158180195232270
of135459410833755
C-Terminal14225941083405382113133191206243275290
Src17255941083325283
Kinase.18205941083355188120146181192
Circulation.3406041083405576107145160193214230268306319
2020;142:2443-2455.67660410833569102136148179210242255290322359391413444476509541553
https://doi.org/10.1161/CIRCULATIONAHA.120.049210.1246604108338598412315016218921024528429931235037241043646950051354457160363365569470974534061410834084116159188204252298339384425439470500534547582618651684716747760
14.3406240085366984
Dickerson4436241083456193123157178206244282
T,74462410833342
Wiczer80562410835773105136170191
T,101562410833341
Waller107562410835889105120154176
A,127062410834155
et134462410833456
al.14196241083324760
Hypertension149862410834476116151173197231269295310348387
and190462410833169108
incident3406341083155386102141177216238
cardiovascular5996341083316587125141180212246273306344360393415
events103563410833467102141163191
following1247634108319577389128180196234274
ibrutinib15426341083155577116139155193209248
initiation.18116341083155469921081411631793406441083387790
Blood.4516441083365290129170183
2019;134:1919-1928.65564410833469101132145175206242254284315347378402433464497532545
https://doi.org/10.1182/blood.2019000840.122164410833860851251521641922122492873033163553774164424765085205525806116456727137297683406541083377790126160192222258294330365402438450
15.3406640085366882
Ping4356641083354987126
L,57466410833145
Ding6316641083466199137
N,78166410834558
Shi8516641083337085
Y,94966410833543
et100566410833456
al.10746641083324760
The114766410833271106
Bruton’s12666641083355694117154192204229
tyrosine15076641083225677114141156193228
kinase17486641083304683116142177
inhibitor1938664108314523406741083375392107130166188
ibrutinib5416741083155475113136151189204243
exerts79767410833466100121145173
immunomodulatory98367410831572130168206244302340380417433465487524545579
effects15756741083345473107140164191
through17796741083226081118156195233
regulation3406841083215595132148180202217255294
of65468410833857
tumor-infiltrating73268410832159117156178197213251269286301324345378400416454493
macrophages.124568410835890122144181221260292331366393407
Oncotarget.167268410834786118155177210231270305327341
2017;8:39218-29.34069410833468100129139174187222255288320351373404439449
https://doi.org/10.18632/oncotarget.16836.804694108337598312314916218920924528329831134937140943546850051254357461064367670273777680884586789992195999410161029106010911127116111951208
16.3407040085366985
Derosa44370410834581102139166199
L,66070410833145
Izzedine7237041083154475109149164202237
H,97870410834457
Albiges10537041083415795111150185212
L,128370410833145
et134670410833456
al.14207041083324760
Hypertension149870410834576116152173198231270296311349387
and190370410833270109
angiotensin34071410833270108123161183217254281295333
system6867141083265885108142199
inhibitors8987141083155390105144160182219240267
in117871410831552
patients12437141083397293108143181202230
with14867141083506688126
metastatic162571410835792114146173196229250265297
renal1935714108321543407241083387085
cell438724108331658196
carcinoma.5477241083316485116131169207265298311
Oncol87172410834786118155171
Rev;105572410833570102115
2016.118372410833569100131145
https://doi.org/10.4081/13417241083375983123149162189209245283298311349371409435468500512547582618650671
oncol.2016.298.34073410833776108145161174210244276307320356390425438
17.3407440085366876
Kappers43574410833568108147183204231
MHW,68574410835599158167
Van87174410833667105
Esch9957441083336092130
JHM,114474410832469124138
et130174410833356
al.13767441083314760
Hypertension145574410834476115151172197231269295310348386
Induced1860744108315539213034075410833165104
by46275410833970
the5507541083226095
Tyrosine6637541083326082119146161199234
Kinase9147541083355290122148183
Inhibitor11157541083155391106145161183220242
Sunitinib137575410833269107123145160198213252
Is164575410831541
Associated17047541083416995134166181213235269308
With3407641083587497135
Increased4967641083155385107141173200235275
Circulating7927641083405577108146161194216231269309
Endothelin-1112176410833371111149171210245261276314337368
Levels.15097641083326699133149175189
Hypertension1719764108344761161521741982322713407741083264180118
2010;56:675-81.47977410833569101133146181216229264298331353389421431
https://doi.org/10.1161/HYPERTENSIONAHA.109.149690.93177410833759841241511631902112472863013143533754134404735055185495776086396617067437798128488829179629941009105721407410834586130172186217249284295325357390425459495507
18.2140840085377188
Rule2250841083367592128
S,23998410833447
Dreyling24688410834669104137154170209249
M,27398410835670
Goy28318410834585117
A,29708410834257
et30488410833558
al.3128841083334963
Ibrutinib3212841083155678118142158197213253
for3487841083195880
the3589841083226298
treatment370984108322448021409410833255114150188211
of23729410833757
relapsed/refractory2450941083215672105145172208248275295330350372406439464501523558
mantle30299410835891130152168204
cell325494108332668298
lymphoma:33739410831547107147186225285318330
extended3724941083356721401041083225593133167207
3.5-year23671041083344782104136170202223
follow2610104108319567287125176
up280710410833776
from29031041083184078136
a3059104108332
pooled311110410833977116132167206
analysis.333710410833270103118150177192218231
Haematologica.35881041083447711217020221401141083226077116156172205239253
2019;104:e211-4.241411410833570102134147178210247260296331363392411449462
https://doi.org/10.3324/haematol.2018.205229.289711410833861861261541671942152522913073213603824224494835155285655986326656907317648008598922140124108322597487123158189220234270304338371406440451
19.21401340085366982
Broccoli22381341083355794127157194210225
A,247913410834155
Argnani255013410834163101139171209224
L,279013410833245
Morigi285113410835593115130169184
A,305113410834155
et312213410833457
al.31951341083314760
Long-Term327113410833169107146168198229250309
Efficacy3596134108332506886118151183216
and214014410833168106
Safety22591441083326482115137170
of244114410833755
Ibrutinib25081441083155374111133148185199237
in275814410831451
the28211441083215893
Treatment29261441083324882113134190225262283
of322114410833655
CLL328814410833970101
Patients:34011441083356687102135173193220232
A3645144108341
Real369814410833569100115
Life21401541083314766100
Experience.225815410833265104140161177212250282315328
JCM.260315410832465120134
2021;10:5845.275415410833569102133141171203216251285322355367
https://doi.org/10.3390/31381541083375983123149162189209245283298311349371409435468500512548581614650674
jcm10245845.214016410831547105135166199231264298334367379
20.21401740085367287
Castillo22401741083407399122138153168206
JJ,24591741083244860
Meid253217410835489104143
K,268817410833550
Gustine275117410834381108131146184219
JN,29831741083246982
et307817410833456
al.31471741083324760
Long-term322017410833169107146168191224246304
follow-up3537174108318567287125176198237276
of214018410833757
ibrutinib22161841083145375113136151189204243
monotherapy247818410835796134172194232267289322361392
in288918410831553
treatment-naive29611841083214377109130188224262283303342374389422456
patients34361841083397293109143181203231
with36861841083506688126
Waldenstrom214019410835890105144180218245268290328387
macroglobulinemia.254719410835891123145183223238277317355371386424460518534566579
Leukemia.314719410833266105135170228243276289
2022;36:532539.345719410833469102137150185220233268302335214020410833467100111
https://doi.org/10.1038/s41375-021-01417-9.2267204108337598312314916218920924528329831134937140943546850051254357560864266769272875878882085387591294597699510321064109511251155117312081219
21.21402140085356880
Byrd22332141083356688125
JC,23702141083246477
Furman24592141083326788145177214
RR,26852141083357184
Coutre278221410833975113135155189
SE,29832141083326476
et307121410833456
al.31392141083314659
Targeting32102141083325980117151173188225263
BTK348521410833568104
with36012141083506587124
Ibrutinib3737214108315532140224108321598196134149188
in234122410831553
Relapsed24062241083367186118157184219258
Chronic26772241083407899136174189221
Lymphocytic291122410833160118157196234266300324340372
Leukemia.329522410833266103133168225240272285
N3593224108345
Engl365122410833270109124
J3788224108324
Med.214023410835488126139
2013;369:32-42.22912341083336697126137171205238250284316336371403415
https://doi.org/10.1056/NEJMoa1215637.271823410833757811191451571832032382752903023393603974224544854975275575916246486937257518058428749039329629921025105810891095
22.21402440085367288
Berglöf22422441083357192130145183203
A,245824410834155
Hamasy252724410834477135167193226
A,276724410834155
Meinke283624410835489104142172206
S,305624410833346
et311524410833457
al.31852441083324860
Targets32592441083336182120155177205
for34782441083185677
Ibrutinib35692441083155476114136152190205244
Beyond214025410833571102140178217
B2372254108336
Cell24232541083407489105
Malignancies.254325410835487102117156194226264296312346373387
Scand29452541083336598136175
J3135254108324
Immunol.317525410831472130168206244260273
2015;82:208217.34632541083346810013014117621022225729132721402641083346695101
https://doi.org/10.1111/sji.12333.22572641083375983122149162188209244283298311349371409435468500512543571598626648672687702715746776810843876889
23.21402740085377590
Tang225227410833362102142
CPS,241627410834077111124
McMullen256227410835689146185201217253293
J,287627410832538
Tam293527410833362122
C.307927410834054
Cardiac31552741083417597136152185219
side33952741083274283119
effects35352741083355575110144169198
of375427410833959
bruton214028410833962101124162202
tyrosine23632841083225779118145160199235
kinase26202841083304786119146182
(BTK)28232841083195690128150
inhibitors.29942841083155493109149165188226248276290
Leukemia330628410833267105136172231247279
&3607284108340
Lymphoma.366828410833261121214029410833978117176209222
2018;59:1554-1564.238329410833569102133145181214227257288321357380411442477514526
https://doi.org/10.1080/10428129302941083386085125152165192213249288303317355377416442476508521552584620656681714746783816850882
94.2017.1375110.21403041083347083119153184214220251281313345377404436448
24.21403140085377389
Ganatra225131410834579118151174196231
S,250331410833347
Sharma257131410833473106128188222
A,281531410834156
Shah289331410833372106145
S,306031410833346
et312831410833558
al.32073141083334963
Ibrutinib-Associated32913141083155678118141157196212253277320349376416450466499214032410832258100
Atrial22693241083426588105139156
Fibrillation.24543241083345091115132149165199223240280320335
JACC:281832410832567109149164
Clinical30113241083415874114131165199216
Electrophysiology.32573241083335087121147170210252292325354370410428468510544555
2018;4:1491-500.214033410833468100131143178190220251284316335369403439451
https://doi.org/10.1016/j.jacep.2018.06.004.2604334108338598412315016218921024528429931235037241043646950051354457560763866367969270874077380684685889492896099110041039107510881124116011961208
25.21403440085367287
Lentz224334410833166104125156
R,241434410833650
Feinglass24793441083326682120159174206233259
J,275434410832436
Ma280534410835587
S,290834410833245
et296834410833457
al.30403441083324760
Risk31163441083355177107
factors32383441083185284108145166194
for34473441083195678
the35403441083226095
development36503441083397310614021403541083155393151186224245
of240535410833857
atrial2482354108332537590122138
fibrillation2640354108317347394110125140172194209247286
on294635410833775
ibrutinib30413541083155476114136152190205244
treatment.33053541083214377109131189224262283297
Leukemia362235410833165103133167214036410835772104
&2260364108340
Lymphoma.231636410833159118157196234292325338
2019;60:1447-1453.267036410833468100130143179214227257288325357376407438471504516
https://doi.org/10.10832023641083385983123150162189209245283299312350371409436469500513544575610
0/10428194.2018.1533129.21403741083345992123159192226258288324336372406438469483513543576609640670704715
26.21403840085367287
Alexandre22483841083415791123156194233254288
J,255738410832436
Moslehi261338410835593120135170209224
JJ,28573841083244860
Bersell29383841083357092119154170185
KR.31433841083357287
Anticancer325038410834179101116148181219252285307
drug-induced35773841083385998137159175213214039410833977110144185
cardiac23463941083326587126142175207
rhythm25753941083216091117156215
disorders:28113941083395481120142181217239267280
Current311239410834078100122157196218
knowledge335139410833070109161178213254294329
and370239410833271111
basic214040410833973100115148
underlying230940410833876116152173190222238277317
mechanisms.264740410835894127166199237253279338365379
Pharmacology304740410833674107128188221254291308347387420
&3488404108339
Therapeutics.35484041083337310913116420424121404141083386176109137151
2018;189:89-103.231241410833469102133146176208243256292327351382414448461
https://doi.org/10.1016/j.pharmthera.2018.04.009.2794414108337598412415216419221324928830431735637841744347750952255358561864967569170574578581783989892095999521404241083215467103137169200213248285297332368404415
27.21404340085356978
Joung22304341083246198135173
B.241543410833548
Risk24754341083355075104
Factor25914341083326092115151172
Management277543410835485122154192226282316354374
for31614341083185576
Atrial3249434108340618297128142
Fibrillation.34034341083324785106121135150181202217254291304
Korean37194341083347121404441083205485122
Circ22754441083395475105
J.239244410832436
2019;49:794.24414441083336798128140174207219252285320332
https://doi.org/10.4070/kcj.2019.0212.2785444108337588212114715918520524027829330534336440142745949050253657160363666069072173674878481784887888992395598610151027
28.21404540085367288
Brandes22464541083355790128167202228
A,249245410834155
Smit256545410833290105127
MD,2710454108354100111
Ngueyn283945410834584121156188227
BO,30834541083368394
et319545410833456
al.32694541083324760
Risk33474541083355177107
Factor34714541083326294118155177
Management366545410835587125214046410833271106164199237258
in241146410831553
Atrial2477464108341628399131146
Fibrillation.26364641083334887108124139154186208223261300313
Arrhythmia29624641083416284123153178216274289321
&3296464108339
Electrophysiology33484641083334883116140161198238277307334349387403441214047410833870
Review.222347410833570102118152203214
2018;7:118.245047410833468100131143175185215243274287
https://doi.org/10.15420/aer.2018.18.2.275047410833759831221491611882082442822973103483704084344674985105415716066396726977277627837938298638959269399701001101410501062
29.21404840085367185
Coutré223748410834076114136157191
SE,24414841083326477
Furman25304841083336889147179217
RR,27604841083357184
Flinn2857484108332476199136
IW,30064841083157282
et310048410833456
al.31694841083314659
Extended32414841083326488122159198233272
Treatment35254841083335083115136194229266287
with21404941083526891130
Single-Agent22914941083334988128144179203246285321360382
Ibrutinib26944941083155678117140156195211251
at296649410833355
the30424941083226298
420316149410833568103
mg327449410835898
Dose339449410834685113149
Leads356449410833267100140167
to375249410832260
Durable214050410834787109144185202239
Responses240450410833673101142183223251288316
in274550410831555
Chronic282550410834181104143183199233
Lymphocytic308350410833262123164205245279314341357391
Leukemia/349950410833268108139175236252286314
Small214051410833392125141156
Lymphocytic231751410833261121161201240273307333349381
Lymphoma.271951410833261121161201240299332346
Clinical30865141083415672111126159192208
Cancer331651410834074113145180202
Research.35395141083367299135167189221260273
2017;23:1149-1155.214052410833570103133143180215227258287319353377409438469502515
https://doi.org/10.1158/1078-0432.CCR16-1431.2676524108338618612715416719521625329230832236138442345048451753056259062165668371774978381784187991695098499710381077111421405341083346589120151183214224
30.21405440085367489
Chanan-Khan225054410834079112151184223246283323356395
A,266654410834256
Cramer27435441083416296155191213
P,297754410833540
Demirkan303854410834682141157178210244283
F,334254410833339
et340254410833457
al.34805441083334862
Ibrutinib35635441083155577116139155193209249
combined214055410833270130171187227263304
with24655541083526892131
bendamustine261855410834076116156190249288316340356395431
and307155410833372112
rituximab32055541083213761100133149208242283
compared350955410833270130171205227263303
with21405641083516689127
placebo,22875641083395587119153192231243
bendamustine,255156410833874112151183241279305328344381416428
and300056410833270109
rituximab3129564108321365997128144201234273
for34225641083195678
previously35205641083396195127143181219245261292
treated21405741083224377109131165204
chronic23595741083316990128166181213
lymphocytic258757410831547105145183221254288312328360
leukaemia29625741083154987117151186244259291
or326857410833759
small334257410832683116131146
lymphocytic35035741083154710514518322125428821405841083223769
lymphoma222458410831547105144183221280312
(HELIOS):25515841083196396128143191224243254
a2821584108331
randomised,28685841083205391130168227242268303343355
double-blind,323858410833877115154170205228268284299337376388
phase364158410833978110136171
32140594108334
study.21955941083264987126159169
The238459410833372107
Lancet251259410833165103135169191
Oncology.272459410834786118155171209249281291
2016;17:200-211.303659410833468100132144174204214249283320343375406434443
https://doi.35005941083375984123150162189210246284300313
org/10.1016/S1470-2045(15)00465-9.2140604108337599712315618820023126229432535038341444547751053456559963566868671874876680183787391094396510001011
31.21406140085366981
O’Brien22366141083476097118134168206
S,245761410833245
Jones251761410832462101136162
JA,26946141083246478
Coutre278761410833976115137159193
SE,29946141083336578
et308661410833457
al.31576141083324760
Ibrutinib32326141083155475114136151189204243
for34906141083185678
patients35826141083397293109143181203231
with21406241083516689127
relapsed22846241083205570102142168203243
or254462410833759
refractory2620624108320557496129161185222244278
chronic29156241083316990127166181213
lymphocytic314562410831546105144183221254287312327359
leukaemia35216241083155088118151186244259291
with21406341083526892131
17p229363410833565103
deletion24186341083397591127150166206246
(RESONATE-17):26856341083195691126175222265295330353385415436448
a3155634108332
phase320963410833979113140176
2,340763410833548
open-label,347763410833879115155178195229269306322335
multicentre214064410835795110133148180214252273295329
study.24856441083264987126158168
The267064410833272107
Lancet279364410833165103135169191
Oncology.300064410834786118155171209249281291
2016;17:1409-1418.330764410833468100131144174203213243274310345369399431461492505
https://doi.org/10.1016/S1470-2045(16)30212-1.2140654108338598312315016218920924528329931235037140943646950051354357560763866369672675879082384787791294898199810301061107911121147118012111241126112921301
32.21406640085367186
Jain22456641083245671109
P,237366410833539
Keating243066410833570101123139176215
MJ,26646641083548092
Wierda277466410835874108130168200
WG,2992664108358102115
et312566410833456
al.32006641083314760
Long-term327866410833169107146168191225246304
Follow-36016641083326985100138189212
-up214067410832160100
of226067410833858
Treatment23386741083335185117139198233272294
with26526741083516790128
Ibrutinib28016741083155576115138153192207247
and306867410833271110
Rituximab31996741083365174112144160218251290
in351067410831553
Patients35846741083356790105140179200228
with21406841083516689127
High-Risk22836841083456099136159196212238268
Chronic25676841083407899136175190222
Lymphocytic280568410833260119158197235268301326341373
Leukemia.319568410833165103133167225240272286
Clinical34976841083405570108123155188204
Cancer371768410834073214069410833870103125
Research.22796941083357097132164185216254267
2017;23:2154-8.256069410833468100129139174209220255287317352375411425
https://doi.org/10.1158/10780432.CCR-16-1948.29996941083375983122149162188209244283298311349371409435468500512543571601635660693725757791214070410833470103136148188226261283314345369400430466502515
33.21407140085377388
Barr22507141083367092115
P,238671410833641
Robak244871410833676117151182
T,265171410833343
Owen2715714108348102137177
CJ,29137141083416881
et301571410833558
al.30957141083324862
Updated317871410834585126159181216257
Efficacy3456714108334527089122156189223
and370171410833271112
Safety21407241083326584119141175
from23297241083184077136
the24787241083226095
Phase258772410833572105131166
32767724108334
Resonate-228157241083357097135174206228261285316
Study:31447241083335492131163176
Ibrutinib33347241083155475114136152189205244
As359172410834169
First-3674724108332476896119138
-Line21407341083215469107142
Treatment22997341083335084116138196231269290
Option260673410834787109125163201
in282473410831552
Patients28937341083366789104139177199226
65313673410833568
Years32217341083366798120147
and338573410833270109
Older351173410834763102136158
with36867341083506688126
Chronic21407441083407899136175190222
Lymphocytic237774410833260119158196235267301326341373
Leukemia/Small276674410833165103133167225240272299331389421437452
Lymphocytic323374410833260119158197235268301326341373
Leukemia.362274410833165103133167214075410835874107121
Blood.22827541083365291131171185
2016;128:234-234.248875410833569102134147178208243256292327363387419454491504
https://doi.org/10.1182/blood.V128.22.234.234.3013754108338608512515316619321425129030631935838142044648051352655758661765267972073777621407641083377790123157187221234270305317353388423436472507542555
34.21407740085367388
Farooqui22447741083326283120159198236251
MZH,251177410835493137150
Valdez26777741083356782121156185
J,287877410832436
Martyr293077410835487108133166188
S,313477410833345
et319577410833456
al.32677741083324760
Ibrutinib33437741083145375113136151189204243
for36027741083185678
previously369577410833960953940741083324887125152167200
untreated4160741083387798120155187209244284
and44647410833371111
relapsed4596741083205571104143170206246
or48637410833759
refractory494374108321567598131164188226248282
chronic5246741083327092130169184216
lymphocytic5483741083154710739408410833978116149183208224256
leukaemia4217841083155088118152188246261294
with4531841083516790128
TP5346808410833370103137
aberrations:48378410833272108129151185207222261299326339
a519684108332
phase52498410833978110137173
2,54428410833547
single-arm55108410832641803940941083385388111144165223
trial.418194108321435890106119
The43179410833372107
Lancet44419410833265103135169191
Oncology46509410834785117154170208248280
2015;16:169-176.49479410833569100130141171202215245276310333364394425439
https://5403941083385984123150162189209
doi.org/10.1016/S1470-2045(14)71182-9.394010410833876921051431642022292622933063373684004314564895205515836166406717057417747918238548719039359639941028104810831094
35.39401140085367085
Byrd40371141083356788126
JC,41761141083246477
Furman42661141083326888146178216
RR,44951141083357184
Coutre459211410834076114136157191
SE,47961141083326477
et488511410833456
al.49541141083314659
Three-year50261141083327192125160183215248280301
follow-up5339114108319567286124175197235274
of394012410833757
treatment-naïve40101241083224377109131189224262284303342374390422456
and448012410833270109
previously46021241083396094127142180218245260292
treated49071241083224377109131165204
patients51251241083387193108143181203230
with53691241083506688127
CLL550912410834071103
and394013410833168106
SLL40581341083316192
receiving41621341083205385117132163178215253
single-agent44261341083264077115129163185216254288325345
ibrutinib.47831341083145273110132146183197235247
Blood.50421341083344986124162174
2015;125:24972506.52281341083346797126136165194228238272303335367394014410833469103139152
https://doi.org/10.1182/blood-2014-10-606038.4107144108338608412315016318921024528429931235037241043646950151354457260363666370371975779683585888892395498510081039107110951132116712031238127213061319
36.39401540085367288
Awan404115410834191123161
FT,42151541083336877
Addison430515410834079118133159197235
D,455315410834656
Alfraih4622154108341577698131146184
F,481915410833238
et487015410833456
al.49391541083324760
International50121541083155274108129167199221236274313345360
consensus53851541083316810613316820639401641083276591
statement40531641083265083106140199235274296
on437016410833877
the44681641083226197
management458616410835892130163203239298334373395
of500216410833858
cardiovascular50811641083316587126141180213247274307345361394416
risk5518164108321376494
of394017410833757
Bruton’s40171741083365795118155194206231
tyrosine42681741083225678115142157195230
kinase45181741083304785117144179
inhibitors47171741083155391106145161183221242269
in500717410831553
CLL.508017410834072104118
Blood52181741083355189128168
Advances.54061741083418011314618439401841083326795109
2022;6:5516-25.407118410833571105141154191204241275307340364396433445
https://doi.org/10.1182/bloodadvances.2022007938.453818410833861861271551681962182552953113253643874264534885215345665956276626907317487888288699039439771011105139401941083316592105141175208243277313346379412447460
37.39402040085367281
Onitilo404220410834887103126141157196
AA,425920410834185100
Piwuna438020410833550102141180213
TO,46142041083338092
Islam4727204108315425790149
N,489720410834559
et497720410833457
al.50552041083324861
Determinants513720410834682105139161221236275308346369397
of555520410833857
Atrial39402141083416385101134149
Fibrillation41102141083334888110126142157190212228266305
Development443621410834682115150166205245304340378400
among485721410833291130169209
Patients50872141083356890106141180202230
undergoing53382141083377611615117321225139402241083155392
Ibrutinib40522241083155476114137152190205244
Therapy.431722410833272107128161200231242
Clin45792241083405570108
Med470722410835590130
Res.48572241083367197111
2022;20:16-22.498922410833468101136148183217230260291315346381393
https://54032241083375983123149162189209
doi.org/10.3121/cmr.2021.1693.39402341083387692105143164202229262293306341372402434455484542563574610644676708717748779813846858
38.39402440085367288
Mato404124410835487109146
A,420024410834155
Tang42682441083326098137
B,441924410833548
Azmi448024410834172130145
S,463824410833345
et469624410833457
al.47662441083324760
A4839244108341
real-world48932441083215587102124176214235251290
study51962441083264987126158
to536724410832259
assess54392441083325885120147173
the39402541083215993
association40452541083325783121153167199220235272309
of436725410833655
cardiovascular44342541083316384121136173204236262294331345377397
adverse484425410833169101135155182216
events50722541083346599136157184
(CVAEs)52682541083195795132165191208
with54882541083506587124
ibrutinib39402641083155475114136151189204243
as419826410833158
first-line4270264108317345582105125141156194229
(1L)4513264108319507897
treatment46242641083224478109131189224263284
for49222641083185678
patients50142641083387193108143181203230
with52592641083506688126
chronic53992641083327091128166181213
lymphocytic394027410831547105144183221254287312328359
leukaemia43162741083155088118151186244259291
(CLL)46242741083185889121140
in478127410831553
the48502741083226095
United49622741083448196119153192
States.51712741083325386108142169182
EJHaem.537027410833359104136171229242
2023;4:135-144.394028410833468101136147182194224254287309340371408420
https://doi.org/10.1002/jha2.638.43762841083375983122149162189209245283298311349371409435468500512543575611644670686724757791804839873907920
39.39402940085367184
Shanafelt403729410833270102140172191225240263
TD,43122941083337990
Wang441529410835788126165
XV,45932941083387685
Kay46902941083356899
NE,48022941083447790
et490529410833456
al.49742941083324760
Ibrutinib–Rituximab50462941083155475113136151189203242280317332354392423438496528567
or394030410833759
Chemoimmunotherapy401430410834078113171209225282340378416454476514549570603643674
for47033041083195678
Chronic47963041083407899137175190222
Lymphocytic503330410833260119158197235268301326341373
Leukemia.542230410833165103133167394031410835772104117
N4069314108345
Engl412631410833370109124
J4263314108324
Med.429931410835489128141
2019;381:432-443.44533141083346799129141176210242250284316348369405441474486
https://doi.org/10.1056/49523141083375882121148160186207242280295308345367404430463494506537568602636661
NEJMoa1817073.394032410834578105159198231261292323353386419453465
40.39403340085367489
Woyach404333410835794125158190228
JA,42863341083246478
Ruppert437833410833573112152187209233
AS,46263341083417587
Heerema472833410834479114135169227260
NA,500233410834586100
et511633410833457
al.51873341083324760
Ibrutinib52613341083155476114136152190205244
Regimens551933410833570394034410833852109144181207
versus41593441083326586113149175
Chemoimmunotherapy434734410833976111168205220277334371409446468505540560593631662
in502134410831552
Older508534410834763101135156
Patients52533441083356688102137174195222
with54883441083506587124
Untreated394035410834481102123157188210243282
CLL.423535410834071102116
N4364354108344
Engl442135410833269108123
J4557354108324
Med.459335410835489128141
2018;379:2517-2528.47473541083346799129141176208241254288323354383401431466499532545
https://doi.53053541083375882121148160187207242280295308
org/10.1056/NEJMoa1812836.39403641083375997123156188200231262297331356402435462517555588618649681710744778813826
41.39403740085366981
Diamond40373741083456193151189227267
A,432037410834155
Bensken439137410833671109135165199238
WP,46453741083579498
Vu476037410833572
L,484837410833245
et491037410833456
al.49833741083314760
Ibrutinib50593741083155476114136152190205244
Is531937410831541
Associated5377374108341689513316618121339403841083215493
With40453841083567294131
Increased41883841083155283104137168194228267
Cardiovascular44673841083397191129143180211244269301338352384404
Events48833841083336397134155182
and507738410833168107
Major519638410835385100137158
Bleeding53663841083355084118157172209247
in394039410831552
Older400539410834662101136156
CLL417439410834071103
Patients.42893941083356788103138176197224238
JACC:453939410832464103141154
CardioOncology.47053941083407393131146184232270302339354392431463473
2023;5:233-243.519139410833367100134145180191226260293315345377409421
https://doi.org/10.1016/j.jaccao.2023.02.001.39404041083385983123150162189209245283299312350371409436469500513543575607638663679692708740772803836874887923957990102510371072110511181153118912211230
42.39404140085367086
Caldeira40434141083407388127162177198231
D,429141410834556
Alves43634141083415789124150
D,453041410834556
Costa460341410834077103126159
J,477941410832436
et483141410833457
al.49044141083324760
Ibrutinib49814141083155475114136151189204243
increases52414141083155285106140172198233260
the55184141083216095
risk3940424108321366292
of404742410833857
hypertension411942410833868108144165190223261288303341379
and451342410833270109
atrial4637424108332547591123138
fibrillation:4790424108317347395110125141173194210248286298
Systematic51034241083336390113147205237259274306
review54244241083215587103137189
and394043410833270109
meta-analysis.406643410835792115148170202240273288320347362388401
PLoS448543410833566103135
ONE.463743410834793126139
2019;14:e0211228.479343410833569101131144174205217251287320351379409444477491
https://doi.53014341083375983123150162189209245283299312
org/10.1371/journal.pone.0211228.39404441083375997123156188200231261293325347363401440461499532547560600639677712724759792824851881916950963
43.39404540085367186
Leong404345410833166104143182
DP,42424541083458186
Caron43454541083407294131169
F,453145410833339
Hillis4587454108344597489104130
C,473445410834053
et480445410833457
al.48784541083324760
The495545410833272107
risk5079454108320366292
of518845410833757
atrial5262454108332537590122138
fibrillation541745410831734739411012514017239404641083223775113
with40724641083516689127
ibrutinib42184641083155475114136152189204244
use:44814641083376398110
a4610464108332
systematic46614641083265986109143201233255270302
review49824641083215587103137189
and519046410833169108
meta-analysis.5317464108358931151481702032412733940474108315487691118132
Blood.40934741083365292131172185
2016;128:138-140.430047410833569102134147178209243256287317353376408440477490
https://doi.org/10.1182/blood-2016-05-712828.4811474108338608512615316619421525229130732035938242144848251452755958761965368172273877739404841083377799130164196227251288322344375408438471505539552
44.39404940085367490
Sestier40484941083326894118133167189
M,425549410835568
Hillis4342494108344597489104130
C,449149410834053
Fraser45624941083335285112147168
G,474949410834357
et482449410833457
al.48994941083324760
Bruton’s49784941083355695117154193205230
tyrosine52264941083225678115142156194229
kinase54744941083294684116394050410832661
Inhibitors40185041083145290106145160183220241268
and430350410833270109
Cardiotoxicity:44285041083407394132148186207244275290322337360393407
More485250410835492114148
Than501750410833271104142
Just51755041083246289112
Atrial53035041083416384100132147
Fibrillation.54675041083324786108123394051410831530628499137176189
Curr41465141083407698119
Oncol428351410834785117154170
Rep.447051410833671110123
2021;23:113.461051410833468101132141176210222251279309322
https://doi.org/10.1007/49495141083375983123149162189209245283298311349371409435468500512543575611643663
s11912-021-01102-1.39405241083265684114146176196233266298317354386413445477498529538
45.39405340085367186
Heeringa403953410834479114135151188227259
J,431153410832436
Van436053410833667105
Der447753410834681102
Kuip45925341083347186125
DAM,473053410834585140154
Hofman489653410834483102160192230
A,513953410834155
et520753410833456
al.52765341083314760
Prevalence,5348534108335569012215517020524339405441083316577
incidence40305441083155385100139174212244278
and432154410833270109
lifetime4443544108315305084106122179214
risk4671544108320366292
of477654410833857
atrial4846544108332547591123138
fibrillation:4998544108317347394110125140172194209247286298
the53095441083226095
Rotterdam54185441083357395120153175394055410833870128
study.40815541083265088127159169
European42635541083326990127167202234272
Heart454855410834580111133157
Journal.471855410832563101122161193208221
2006;27:949-53.495355410833468104140152187220230265301334358392425437
https://54035541083385984123150162189210
doi.org/10.1093/eurheartj/ehi825.39405641083387692105143164202229262293306337368403436460492530551589624656677702717744775813828863897932944
46.39405740085367388
Špaček404357410833270103134167196
M,425457410835567
Smolej433657410833289127142176191
L,454157410833245
Šimkovič460057410833347104133170201216247
M,486257410835467
e4944574108334
al.49925741083324759
Idelalisib50655741083155488103134149163189203241
plus53215741083385490116
rituximab5452574108320355794125140394058410835789128
versus40855841083316585112149174
ibrutinib42765841083155374112134148185200238
in453158410831552
the46005841083226094
treatment47115841083224276107128185220257278
of500658410833756
relapsed/refractory50795841083215469101139165199238264283316334356388420443479500533
chronic39405941083316888124161175205
lymphocytic415659410831546103141178215246278302316347
leukaemia:45145941083154885114146179236250281292
A4817594108340
real-world4868594108321548499120170206227242279
analysis51585941083326899114144170184209
from53785941083183975132
the55215941083215892
Chronic39406041083407797133171185217
Lymphocytic416860410833159117155193230262295319333364
Leukemia454460410833164101130164221235266
Patients48226041083356687101135172193220
Registry505360410833670108123148170191224
(CLLEAR).52896041083185787119151193228246256
Br555660410833656
J3940614108324
Haematol.397661410834476110167199220256271283
2023;202:40-47.427161410833468100134145179212244256290325348384416421
https://doi.org/10.1111/bjh.18736.47046141083375882120146158184204239277291304341362399425457488500530557584611632671686723736766796828862896908
47.39406240085367079
Bryer40386241083355791125146
E,420462410833245
Itsara4269624108314376498119152
A,444062410834155
Ahn451462410834180118
IE,46516241083154861
et473162410833456
al.48076241083314760
Ibrutinib-Associated48866241083155476114136152190205244267308336363401434449481503536576
Sudden548162410833370109394063410833873111
Death407063410834581113134173
in426263410831452
Patients43336341083356789104139177199226
with45786341083516689127
CLL.472463410834072104117
Blood.48606341083365189128168181
2022;140:4133-4134.506063410833468101136148178209245258293323353386408444475505540553
https://doi.org/10.1182/blood-2022-160397.3940644108338598312315016218920924528329931235037140943646950051354357160263666270271875779583585788892295599010101041107211081141117412071213
48.39406540085367591
Munir405265410835593132147169
T,424265410833342
Pitchford43056541083355073104143162200222261
A,458765410834156
Bloor46636541083365291130152
A,483665410834156
et491365410833457
al.49916541083324761
Sudden507365410833270110150185224
or531765410833860
Cardiac53986541083407495134149182215
Deaths394066410834682114136175202
on416266410833877
Ibrutinib-Based42606641083155576115138154192208247271309342369405445
Therapy472666410833372108130163203235
Were498166410835892114148
Associated51506641083417097136169184217239273313
with54846641083516790128
a3940674108332
Prior39916741083355672110131
History41426741083445985108145167201
of436367410833756
Hypertension443967410834476116151172197231269295310348386
or484567410833759
Cardiac49236741083407394133148180212
Disease51546741083466187122154181216
and538967410833270109
the55186741083216095
Use394068410834469104
of406168410833756
ACE-Inhibitors413368410834180113134151189227242281297319356378405
at455468410833254
Study46246841083325391130162
Entry:48026841083337192114148161
Analysis497968410834179112127159186201227
from52226841083184078136
the53746841083226095
Phase548568410833572105394069410832661
III40156941083153046
NCRI407569410834485121137
FLAIR422669410833263106122158
Trial.4398694108332506597113125
Blood.45386941083355189128167180
2021;138:2636-2636.473269410833569102133141171201236248283317351385408439473507541555
https://doi.53016941083375983123149162189209245283298311
org/10.1182/blood-2021-152167.39407041083375997123156188200231259290323350390406444483522545576610642674693723753787818849882888
49.39407140085367285
Shanafelt403971410833270103141173192226242264
TD,43187141083327990
Parikh44227141083356788104134173
SA,46097141083337488
Noseworthy471171410834583110145196234255280318349
PA,50747141083357287
et517571410833456
al.52457141083324760
Atrial5320714108340628399131146
fibrillation5480714108317347395110394072410831530628499137176
in413172410831452
patients41997241083387193108143181203230
with44447241083516789127
chronic45867241083327091128166181213
lymphocytic481572410831446105144183221253287312327359
leukemia51897241083155088118152210225257
(CLL).54617241083195889121141151
Leukemia394073410833166103133168225241273
&4227734108340
Lymphoma.428173410833260119158196235293325339
2017;58:1630-9.463573410833468100129139174208220250281315349373408419
https://doi.org/10.150697341083385983123150162189209245283299312350371409436469500513543
080/10428194.2016.1257795.394074410833470105129163194230263297328359394407443477509540553584614649682717750784796
Další39407619011061106128164186
literatura414176190110234475119150195224274305349
u45057619011051
autora4571761901104695126175205250
a39407719011046
na4001771901105196
www.onkologiecs.cz41127719011067136204221271321365414436485536558603643680701740780